Kristine Ziemba, MD
Neurology · Charlottesville, VANPI 1811155864
Payments from drug & device makers
What this record shows
Neuropace, Inc. accounts for 63.2% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $1,645 and has fallen 95.8% since, to $70 in 2025.
Across 38 payments — averaging $61.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuropace, Inc.$1K
- Livanova USA, Inc.$200
- AbbVie$171
- Acadia Pharmaceuticals Inc$130
- Jazz Pharmaceuticals Inc.$114
- Bristol Myers Squibb$81
- plus $157 from 5 others
What the payments were for
- Travel & lodging$1,07446%
- Food & beverage$1,24554%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuropace, Inc. | 5 | $1,467 |
| Livanova USA, Inc. | 2 | $200 |
| AbbVie | 11 | $171 |
| Acadia Pharmaceuticals Inc | 8 | $130 |
| Jazz Pharmaceuticals Inc. | 1 | $114 |
| Bristol Myers Squibb | 4 | $81 |
| SK Life Science, Inc. | 1 | $76 |
| Sunovion Pharmaceuticals Inc. | 3 | $35 |
| Pfizer | 1 | $17 |
| Sanofi | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RNS System$1,320
- VNS Therapy$138
- Epidiolex$114
How this compares
$2,319 in reported general payments places this provider in the 55th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 55 | $4,879 |
| Divalproex Sodium | 19 | $3,277 |
| Levetiracetam | 77 | $3,101 |
| Oxcarbazepine | 25 | $2,781 |
| Clobazam | 35 | $1,982 |
| Zonisamide | 22 | $827 |
| Lamotrigine | 29 | $663 |
| Levetiracetam ErLevetiracetam | 14 | $662 |
| Topiramate | 21 | $347 |
| Phenobarbital | 11 | $329 |
Paid to pharmacies, not to this prescriber.
Other neurology in Charlottesville
- Robert ShinCharlottesville$1.7M
- Brian WeinshenkerCharlottesville$195K
- Robert SawyerCharlottesville$55K
- Nathan FountainCharlottesville$45K
- Helen Dainton-HowardCharlottesville$41K
- Alissa HiginbothamCharlottesville$37K
- Ramsey FalconerAlexandria$2M
- Heidi CraytonVienna$1.5M
- Mark LandrioWinchester$631K
- Catherine HamRichmond$603K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.